Abstract

Assays to study cancer cell responses to pharmacologic or genetic perturbations are typically restricted to using simple phenotypic readouts such as proliferation rate. Information-rich assays, such as gene-expression profiling, have generally not permitted efficient profiling of a given perturbation across multiple cellular contexts. Here, we develop MIX-Seq, a method for multiplexed transcriptional profiling of post-perturbation responses across a mixture of samples with single-cell resolution, using SNP-based computational demultiplexing of single-cell RNA-sequencing data. We show that MIX-Seq can be used to profile responses to chemical or genetic perturbations across pools of 100 or more cancer cell lines. We combine it with Cell Hashing to further multiplex additional experimental conditions, such as post-treatment time points or drug doses. Analyzing the high-content readout of scRNA-seq reveals both shared and context-specific transcriptional response components that can identify drug mechanism of action and enable prediction of long-term cell viability from short-term transcriptional responses to treatment.

Large-scale screens of chemical and genetic vulnerabilities in cancer are typically limited to simple readouts of cell viability. Here, the authors develop a method for profiling post-perturbation transcriptional responses across large pools of cancer cell lines, enabling deep characterization of shared and context-specific responses.

Details

Title
Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action
Author
McFarland, James M 1   VIAFID ORCID Logo  ; Paolella, Brenton R 1   VIAFID ORCID Logo  ; Warren, Allison 1 ; Geiger-Schuller, Kathryn 2   VIAFID ORCID Logo  ; Shibue Tsukasa 1 ; Rothberg, Michael 1 ; Kuksenko Olena 2 ; Colgan, William N 1   VIAFID ORCID Logo  ; Jones, Andrew 1 ; Chambers, Emily 1 ; Dionne, Danielle 2 ; Bender, Samantha 1 ; Wolpin, Brian M 3 ; Ghandi Mahmoud 1   VIAFID ORCID Logo  ; Tirosh Itay 4 ; Rozenblatt-Rosen Orit 2 ; Roth, Jennifer A 1 ; Golub, Todd R 5   VIAFID ORCID Logo  ; Regev Aviv 6   VIAFID ORCID Logo  ; Aguirre, Andrew J 7   VIAFID ORCID Logo  ; Vazquez Francisca 1   VIAFID ORCID Logo  ; Tsherniak Aviad 1   VIAFID ORCID Logo 

 Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34) 
 Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34); Broad Institute of MIT and Harvard, Klarman Cell Observatory, Cambridge, USA (GRID:grid.66859.34) 
 Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Brigham and Women’s Hospital, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); Dana Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
 Broad Institute of MIT and Harvard, Klarman Cell Observatory, Cambridge, USA (GRID:grid.66859.34); Weizmann Institute of Science, Department of Molecular Cell Biology, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563) 
 Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana Farber Cancer Institute, Department of Pediatric Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Howard Hughes Medical Institute, Chevy Chase, USA (GRID:grid.413575.1) (ISNI:0000 0001 2167 1581) 
 Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34); Broad Institute of MIT and Harvard, Klarman Cell Observatory, Cambridge, USA (GRID:grid.66859.34); Howard Hughes Medical Institute, Chevy Chase, USA (GRID:grid.413575.1) (ISNI:0000 0001 2167 1581); Koch Institute of Integrative Cancer Research, Cambridge, USA (GRID:grid.413575.1); MIT, Department of Biology, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786) 
 Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Brigham and Women’s Hospital, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); Dana Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2437643547
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.